Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

An­oth­er Big Phar­ma is en­ter­ing the Covid-19 an­ti­body hunt.

Ab­b­Vie has an­nounced a col­lab­o­ra­tion with the Nether­lands’ Utrecht Uni­ver­si­ty and Eras­mus Med­ical Cen­ter and the Chi­nese-Dutch biotech Har­bour Bio­med to de­vel­op a neu­tral­iz­ing an­ti­body that can treat Covid-19. The an­ti­body, called 47D11, was dis­cov­ered by Ab­b­Vie’s three part­ners, and Ab­b­Vie will sup­port ear­ly pre­clin­i­cal work, while prepar­ing for lat­er pre­clin­i­cal and clin­i­cal de­vel­op­ment. Re­searchers de­scribed the an­ti­body in Na­ture Com­mu­ni­ca­tions last month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.